Want to see AURA full AI Analyst Report?
Top Page
Aura Biosciences Inc
(NASDAQ:AURA)
Select Model
Select Model
Rating:54Neutral
Price Target:
$8.00
▲(11.73% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn implying future financing risk). Technicals are comparatively supportive with price above major moving averages and positive MACD, while valuation is constrained by negative earnings and no indicated dividend. Corporate events are mixed, balancing runway extension against increased dilution capacity and restructuring risk.
Positive Factors
Late-stage clinical progress (Phase 3, SPA)
Completion of Phase 3 enrollment under an FDA Special Protocol Assessment materially reduces regulatory design risk and timing uncertainty. This increases the probability that bel-sar can advance toward approval as a frontline, vision-preserving ocular therapy, improving long-term commercial prospects if efficacy is confirmed.
Negative Factors
No revenue and widening net losses
As a clinical-stage biotech, Aura lacks product revenue while net losses have materially increased. Persistent negative earnings mean the business cannot self-fund development or commercialization, raising structural dependence on external capital and increasing medium-term execution risk if clinical outcomes delay or fail.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical progress (Phase 3, SPA)
Completion of Phase 3 enrollment under an FDA Special Protocol Assessment materially reduces regulatory design risk and timing uncertainty. This increases the probability that bel-sar can advance toward approval as a frontline, vision-preserving ocular therapy, improving long-term commercial prospects if efficacy is confirmed.
Read all positive factors
Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$797.49M
Dividend YieldN/A
Average Volume (3M)616.86K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS Growth9.05%
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.78
Shares Outstanding103,704,810
10 Day Avg. Volume397,740
30 Day Avg. Volume616,855
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.50Price Target Upside186.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Aura Biosciences Inc Business Overview & Revenue Model
Company Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platfo...
How the Company Makes Money
As a clinical-stage biotechnology company, Aura Biosciences has not established ongoing product sales in its public disclosures; therefore, recurring revenue from commercial products is null. The company funds operations primarily through financin...
Aura Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -1.29M | 0.00 | 0.00 |
| EBITDA | -131.65M | -104.95M | -85.58M | -74.98M | -57.59M | -34.41M |
| Net Income | -131.01M | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M |
Balance Sheet | ||||||
| Total Assets | 348.13M | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M |
| Cash, Cash Equivalents and Short-Term Investments | 323.84M | 144.24M | 151.09M | 226.15M | 188.81M | 149.06M |
| Total Debt | 16.59M | 17.38M | 18.77M | 19.56M | 20.86M | 975.00K |
| Total Liabilities | 32.86M | 32.52M | 30.53M | 29.23M | 28.35M | 7.71M |
| Stockholders Equity | 315.27M | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M |
Cash Flow | ||||||
| Free Cash Flow | -102.65M | -85.19M | -81.06M | -64.56M | -55.70M | -34.53M |
| Operating Cash Flow | -102.31M | -84.74M | -79.81M | -63.85M | -54.60M | -32.41M |
| Investing Cash Flow | -185.33M | 35.59M | 68.82M | -113.96M | -67.87M | -2.13M |
| Financing Cash Flow | 469.17M | 77.16M | 1.59M | 97.29M | 95.63M | 166.26M |
Aura Biosciences Inc Technical Analysis
Positive
7.16
Price Trends
7.00
Positive
7.13
Positive
6.45
Positive
Market Momentum
0.21
Negative
57.56
Neutral
62.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 7.16 is below the 20-day moving average (MA) of 7.32, above the 50-day MA of 7.00, and above the 200-day MA of 6.45, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 62.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.
Aura Biosciences Inc Risk Analysis
Aura Biosciences Inc disclosed 69 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aura Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $637.25M | -4.48 | -41.33% | ― | 278712.12% | 26.59% | |
56 Neutral | $670.88M | 59.91 | -0.02% | ― | 125.12% | 98.69% | |
54 Neutral | $797.49M | -4.32 | -73.18% | ― | ― | 9.05% | |
54 Neutral | $1.00B | -4.56 | -106.15% | ― | ― | 10.96% | |
52 Neutral | $928.09M | -12.57 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $195.56M | -1.33 | -114.26% | ― | -62.08% | -2.62% |
* Healthcare Sector Average
AURA
Aura Biosciences Inc
7.69
1.00
14.95%
ASMB
Assembly Biosciences
32.95
7.19
27.91%
KRRO
Korro Bio
13.28
-6.44
-32.66%
ANNX
Annexon Biosciences
5.29
2.94
125.11%
FDMT
4D Molecular Therapeutics
12.19
4.92
67.68%
DSGN
Design Therapeutics
14.83
9.43
174.63%
Aura Biosciences Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Aura Biosciences Restructures, Refocuses on Ocular Oncology
Negative
Aug 11, 2026
Aura Biosciences reported second-quarter 2026 results on August 11, 2026, highlighting full enrollment of its Phase 3 CoMpass trial in early choroidal melanoma, with 108 patients and topline data expected in the second half of 2027. The trial, con...
Business Operations and StrategyShareholder Meetings
Aura Biosciences Expands Authorized Shares and Incentive Plan
Positive
Aug 5, 2026
On August 5, 2026, Aura Biosciences, Inc. held a Special Meeting of Stockholders at which a quorum was present, with 89,490,726 of 103,436,416 eligible common shares represented in person or by proxy. Stockholders approved an amendment to increase...
Business Operations and StrategyExecutive/Board Changes
Aura Biosciences strengthens board with new independent director
Positive
Jul 8, 2026
On July 3, 2026, Aura Biosciences expanded its board from six to seven members and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director, effective July 7, 2026, with his term running until the 2029 annual meeting....
Executive/Board ChangesShareholder Meetings
Aura Biosciences Announces Results of 2026 Annual Meeting
Positive
Jun 11, 2026
On June 11, 2026, Aura Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve on the board until the 2029 Annual Meeting, reinforcing continu...
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresPrivate Placements and Financing
Aura Biosciences reports Q1 results, appoints new CEO
Positive
May 11, 2026
On May 11, 2026, Aura Biosciences reported first-quarter 2026 results and business developments, highlighting continued progress of its global Phase 3 CoMpass trial of bel-sar in early choroidal melanoma, which is expected to complete enrollment b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.